Analystreport

Reata Pharmaceuticals, Inc. (NASDAQ: RETA) had its price target lowered by analysts at Barclays PLC from $180.00 to $43.00. They now have an "overweight" rating on

Reata Pharmaceuticals, Inc. - Class A  (RETA) 
Last reata pharmaceuticals, inc. - class a earnings: 2/19 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.reatapharma.com